Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06542250 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
A Phase 1 study of B-cell Malignancies, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
- 20
- Study locations
NCT06542250 is a Phase 1 study of B-cell Malignancies that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 174 participants, below the 305-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06542250, a Phase 1 study of B-cell Malignancies, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Conditions Studied
Interventions
- DRUG AZD5492
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Nedlands
- Research Site - Hangzhou
- Research Site - Shanghai
- Research Site - København Ø
- Research Site - Pessac
- Research Site - Villejuif
- Research Site - München
New York
- Research Site - New York
- Research Site - New York
North Carolina
- Research Site - Charlotte
- Research Site - Winston-Salem
California
- Research Site - La Jolla
Massachusetts
- Research Site - Boston
New Jersey
- Research Site - Hackensack
Texas
- Research Site - Houston
Washington
- Research Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2028-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06542250
The ClinicalTrials.gov registry entry for NCT06542250 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (43% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AZD5492 is the first listed.
NCT06542250 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06542250 about?
NCT06542250 is a clinical study titled "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.". This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
What is the current status of trial NCT06542250?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2024-09-18. Estimated completion is 2028-02-14.
What conditions does trial NCT06542250 study?
This clinical trial studies the following conditions: B-cell Malignancies.
What interventions are being tested in trial NCT06542250?
The interventions under investigation include: AZD5492 (DRUG).
Who is sponsoring clinical trial NCT06542250?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06542250 being conducted?
This trial has 20 study locations across California, Massachusetts, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
COMPLETED · Phase 1
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
-
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.